Patent intelligence · US
US 12036278
Smallpox vaccine for cancer treatment
Smallpox vaccine for cancer treatment
Patent details — US 12036278
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 16, 2024
- Expiration
- Jul 11, 2044
- Applicant
- Calidi Biotherapeutics (Nevada), Inc.
- Claims
- 19
- CPC classes
- A61K, A61K2039/515, A61K2039/525, A61K2039/5254
Quick answer
US 12036278 (Smallpox vaccine for cancer treatment) is held by Calidi Biotherapeutics (Nevada), Inc.. Status: granted. Granted Jul 16, 2024. Expires Jul 11, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Calidi Biotherapeutics (Nevada), Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2039/515, A61K2039/525, A61K2039/5254, A61K2039/55, A61K2039/585
More from Calidi Biotherapeutics (Nevada), Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11655455
Enhanced systems for cell-mediated oncolytic viral therapy
granted -
US 11607450
Smallpox vaccine for cancer treatment
granted -
US 11505782
Cell-based vehicles for potentiation of viral therapy
granted -
US 11285194
Combination immunotherapy approach for treatment of cancer
granted -
US 10857225
Smallpox vaccine for cancer treatment
granted -
US 10105436
Smallpox vaccine for cancer treatment
granted
Frequently asked questions
What is US patent 12036278?
US 12036278 (Smallpox vaccine for cancer treatment) is held by Calidi Biotherapeutics (Nevada), Inc.. Status: granted. Granted Jul 16, 2024. Expires Jul 11, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12036278?
Calidi Biotherapeutics (Nevada), Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12036278 expire?
Our index shows an expiration date of Jul 11, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.